Mr. Aaron Benson reports

ARCH BIOPARTNERS CLOSES NON-BROKERED PRIVATE PLACEMENT

Arch Biopartners Inc. has closed a non-brokered private placement offering of 576,923 common shares priced at $1.04 per common share for gross proceeds of $600,000.

The final amount of the offering was an increase of $100,000 from the amount originally disclosed to the market on Nov. 10, 2025. The proceeds of the offering will be used by Arch as general working capital and for certain operating expenses that are not covered by the company's human trial funding grants. The offering is subject to certain conditions, including, but not limited to, the receipt of applicable regulatory approvals, including final approval from the TSX Venture Exchange.

The offering involved the issuance of 480,923 common shares to an officer of the company and therefore a related party (as such term is defined under Multilateral Instrument 61-101, Protection of Minority Security Holders in Special Transactions) and therefore constitutes a related party transaction under MI 61-101. This transaction is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 pursuant to sections 5.5(a) and 5.7(a) of MI 61-101, as the fair market value of the common shares distributed and the consideration received from the related party in the private placement does not exceed 25 per cent of the company's market capitalization.

All common shares issued in connection with the offering are subject to a hold period of four months and one day from the closing date. There were no finders' fees paid in connection with the offering.

There is no material fact or material change about the company that has not been generally disclosed.

About Arch Biopartners Inc.

Arch Biopartners is a therapeutic biotech company developing novel drugs for acute kidney injury (AKI) and chronic kidney diseases (CKD). The company is advancing an integrated program that includes new treatments targeting inflammation- and toxin-related kidney injury.

Arch's development pipeline includes:

• LSALT peptide: phase II trial targeting cardiac surgery associated-AKI;
• Cilastatin: repurposed drug in phase II trial targeting toxin-induced AKI;
• CKD therapeutics: preclinical program targeting chronic kidney disease.

These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting more than 800 million patients worldwide.

The company has 66,933,289 common shares outstanding.

We seek Safe Harbor.